AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27146963 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 204
Study 24524385 — intervention group
Group type: EXPERIMENTAL
Intervention: 3W program (worksite management intervention)
Number of subjects: 1207
Study 24524385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1207
Study 23070101 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine Artery Embolization (UAE)
Number of subjects: 157
Study 23070101 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 157
Study 20462569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 106
Study 20462569 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 106
Study 20462569 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference match
Number of subjects: 106
Study 18252894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (n = 9)
Number of subjects: 16
Study 18252894 — intervention group
Group type: COMPARATOR
Intervention: Diet only (n = 7)
Number of subjects: 16
Study 16607924 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year
Number of subjects: 105
Study 14606783 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional inferior alveolar nerve block with needle bevel oriented away from the mandibular ramus
Number of subjects: 64
Study 14606783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional-needle-rotation technique using the Wand II anesthesia system
Number of subjects: 64
Study 11001241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (2.5 mg three times daily)
Number of subjects: 25
Study 11001241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9003110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day, n = 151)
Number of subjects: 305
Study 9003110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 154)
Number of subjects: 305
Study 1468283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral GP (glipizide) taken without food after 4 weeks of OD therapy
Number of subjects: 14
Study 1468283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral GB (glyburide) taken without food after 4 weeks of OD therapy
Number of subjects: 14
Study 1468283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral GP taken without food after 4 weeks of TD therapy
Number of subjects: 14
Study 1468283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral GB taken without food after 4 weeks of TD therapy
Number of subjects: 14
Study 1468283 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 14
Study 6138597 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg four times a day for 10 days)
Number of subjects: 101
Study 6138597 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (500 mg four times a day for 10 days)
Number of subjects: 101
Study 29749803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laycarer prepares, labels and stores injections
Number of subjects: 93
Study 29749803 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered nurse prepares injections
Number of subjects: 93
Study 29749803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist prepares injections
Number of subjects: 93
Study 29749803 — intervention group
Group type: COMPARATOR
Intervention: Laycarer preparation vs nurse or pharmacist preparation
Number of subjects: 93
Study 29749803 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience with injecting
Number of subjects: 93
Study 27274999 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Personalized Peptide Vaccination (PPV)
Number of subjects: 0
Study 27274999 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus Placebo
Number of subjects: 0
Study 24993352 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill Desk Group
Number of subjects: 41
Study 19928392 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal infrared imaging (TIRI)
Number of subjects: 27
Study 15853281 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential-teaching method entitled 'To be Touched by AIDS' with an affective component involving an African-American female who is an HIV-Positive intravenous drug user.
Number of subjects: 70
Study 15853281 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture and discussion method.
Number of subjects: 70
Study 15853281 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential-teaching method.
Number of subjects: 70
Study 11680552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 11680552 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 0
Study 9559600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg i.v. three times daily for 5 days)
Number of subjects: 41
Study 9559600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9559600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 41
Study 7889608 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Number of subjects: 12
Study 7889608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dopamine infusion (5 micrograms/kg/min i.v.) for 15-21 hours
Number of subjects: 12
Study 3062558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein formula (F1.3) containing 1.3 g protein/100 ml
Number of subjects: 20
Study 3062558 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein formula (F1.8) containing 1.8 g protein/100 ml
Number of subjects: 20
Study 3062558 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed (BF)
Number of subjects: 20
Study 3062558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein formula (F1.3)
Number of subjects: 20
Study 3062558 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein formula (F1.8)
Number of subjects: 20
Study 11277602 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (mean dose 89.1 +/- 8.2 mg/day)
Number of subjects: 81
Study 11277602 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine maintenance treatment (full doses for 4-6 months)
Number of subjects: 81
Study 11277602 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution after tapering clomipramine
Number of subjects: 81
Study 11277602 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine discontinuation
Number of subjects: 81
Study 31269902 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical records
Number of subjects: 759
Study 31269902 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-administered questionnaires (SAQs)
Number of subjects: 759
Study 30143567 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation for moderate acute malnutrition
Number of subjects: 0
Study 27256731 — intervention group
Group type: EXPERIMENTAL
Intervention: High lead exposure group (cord blood lead >0.48 μmol/L)
Number of subjects: 120
Study 27256731 — intervention group
Group type: COMPARATOR
Intervention: Control group (cord blood lead <0.48 μmol/L)
Number of subjects: 120
Study 25230290 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir (PrEP)
Number of subjects: 470
Study 23017356 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g n3-FA/day
Number of subjects: 53
Study 23017356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 23017356 — intervention group
Group type: COMPARATOR
Intervention: H(2)O (control)
Number of subjects: 53
Study 20931547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pluvio® (a combination of plant extracts including avocado and soya oil, and a high dose of Urtica Dioica)
Number of subjects: 0
Study 20931547 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0
Study 17619832 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Confusion Scale (QCS)
Number of subjects: 666
Study 17619832 — intervention group
Group type: COMPARATOR
Intervention: Mini-Mental Status Exam (MMSE)
Number of subjects: 666
Study 16110205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (CHX) gel treatment
Number of subjects: 151
Study 16110205 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo gel or no gel treatment)
Number of subjects: 151
Study 12171954 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 3
Study 12171954 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 200 micro g four times daily
Number of subjects: 3
Study 12171954 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 3
Study 10522580 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain 2-chloroprocaine 0.5%
Number of subjects: 78
Study 10522580 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized 2-chloroprocaine 0.5%
Number of subjects: 78
Study 10522580 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5%
Number of subjects: 78
Study 7577205 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with bone marrow transplant
Number of subjects: 0
Study 1823066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg t.i.d. for 8 weeks
Number of subjects: 120
Study 1823066 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.i.d. for 8 weeks
Number of subjects: 120
Study 1823066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride and Ranitidine (comparison)
Number of subjects: 120
Study 1823066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 120
Study 1823066 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 120
Study 6162015 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of plasma levels of anti-epileptic drugs (Group A)
Number of subjects: 127
Study 6162015 — intervention group
Group type: COMPARATOR
Intervention: No knowledge of plasma levels of anti-epileptic drugs (Group B)
Number of subjects: 127
Study 6162015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 127
Study 30873060 — intervention group
Group type: EXPERIMENTAL
Intervention: Be a Mom intervention
Number of subjects: 194
Study 30873060 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 194
Study 26263223 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n = 28)
Number of subjects: 107
Study 26263223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 27)
Number of subjects: 107
Study 25468896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (10 mg/d) and Zeaxanthin (2 mg/d)
Number of subjects: 115
Study 25468896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 21989119 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Group Behavioral Treatment
Number of subjects: 40
Study 21989119 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study 19647607 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI)
Number of subjects: 350000
Study 19647607 — intervention group
Group type: COMPARATOR
Intervention: Usual services (comparison)
Number of subjects: 350000
Study 17473202 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (0.11 +/- 0.05 units/kg/d) plus best available palliative support
Number of subjects: 138
Study 17473202 — intervention group
Group type: COMPARATOR
Intervention: Best available palliative support
Number of subjects: 138
Study 15185770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% amino acids/1.4% glycerol solution
Number of subjects: 10
Study 15185770 — intervention group
Group type: COMPARATOR
Intervention: 2.27% glucose solution (control)
Number of subjects: 10
Study 12195263 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 0
Study 12195263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9822092 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg three times daily)
Number of subjects: 92
Study 9822092 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study 8121735 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, family‐based intervention
Number of subjects: 34
Study 2572566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol 200 mg daily
Number of subjects: 20
Study 2572566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol 400 mg daily
Number of subjects: 20
Study 2572566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1149359 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine (1.6 and 5.9 mug/kg/min)
Number of subjects: 5
Study 1149359 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.015 and 0.026 mug/kg/min)
Number of subjects: 5
Study 1149359 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 5
Study 1149359 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.125 mg/kg)
Number of subjects: 5
Study 31281606 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercises conducted by a yoga trainer and a psychiatrist or clinical psychologist expert in yoga
Number of subjects: 30
Study 31281606 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 29092993 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU)
Number of subjects: 100
Study 29092993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25840499 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department and home intervention
Number of subjects: 100
Study 25840499 — intervention group
Group type: EXPERIMENTAL
Intervention: High SABA use
Number of subjects: 100
Study 25840499 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid fills
Number of subjects: 100
Study 25840499 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cockroach sensitization
Number of subjects: 100
Study 22739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) plus Methotrexate (MTX) 15 mg/week
Number of subjects: 172
Study 22739990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) plus Methotrexate (MTX) 15 mg/week
Number of subjects: 172
Study 21190405 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based program as an adjunct to educator-delivered prevention intervention
Number of subjects: 0
Study 18329197 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (cromolyn sodium nasal spray)
Number of subjects: 5
Study 18329197 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (cromolyn sodium nasal spray)
Number of subjects: 5
Study 17262145 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (NaOCl)
Number of subjects: 111
Study 17262145 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (NaOCl)
Number of subjects: 111
Study 17262145 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite (NaOCl)
Number of subjects: 111
Study 17262145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 111
Study 12585948 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention for children whose mothers had less than a high school education
Number of subjects: 296
Study 12585948 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cognitive improvement
Number of subjects: 296
Study 12585948 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with early-onset IVH and significant CNS injury
Number of subjects: 296
Study 12585948 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age, residence in a 2-parent household, higher levels of maternal education
Number of subjects: 296
Study 10615848 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion
Number of subjects: 37247
Study 10615848 — intervention group
Group type: COMPARATOR
Intervention: No induced abortion (control group)
Number of subjects: 37247
Study 10615848 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion with age at first abortion <20 years
Number of subjects: 37247
Study 10615848 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion after first birth
Number of subjects: 37247
Study 10615848 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion with no prior births
Number of subjects: 37247
Study 10615848 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion with early termination (0-2 months)
Number of subjects: 37247
Study 9256573 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session Primary and Secondary Control Enhancement Training program
Number of subjects: 0
Study 9256573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8390970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 1.0 g
Number of subjects: 6
Study 8390970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 3.0 g
Number of subjects: 6
Study 8390970 — intervention group
Group type: COMPARATOR
Intervention: Control (water only)
Number of subjects: 6
Study 3089073 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (2-6 patches per day; mean 3.5)
Number of subjects: 20
Study 3089073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3089073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 3089073 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 20
Study 31907002 — intervention group
Group type: EXPERIMENTAL
Intervention: Metta-based group meditation and individual cognitive behavioral therapy (MeCBT)
Number of subjects: 48
Study 31907002 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 48
Study 31907002 — intervention group
Group type: EXPERIMENTAL
Intervention: Metta-based group meditation
Number of subjects: 48
Study 31323599 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook discussion group intervention with motivational pictures, texts, and discussions
Number of subjects: 375
Study 31323599 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook discussion group intervention
Number of subjects: 375
Study 31323599 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sufficient physical activity
Number of subjects: 375
Study 27256016 — intervention group
Group type: COMPARATOR
Intervention: zoledronic acid (ZA)
Number of subjects: 707
Study 27256016 — intervention group
Group type: COMPARATOR
Intervention: strontium-89 (Sr89)
Number of subjects: 707
Study 26180346 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic recreation program for 3 months
Number of subjects: 32
Study 26180346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic recreation program)
Number of subjects: 32
Study 24755130 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine with flurbiprofen
Number of subjects: 60
Study 24755130 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 60
Study 22890503 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum (mean 3.8 g/day, 2.9 times/day) for 13 months
Number of subjects: 107
Study 22890503 — intervention group
Group type: COMPARATOR
Intervention: No gum (control group)
Number of subjects: 107
Study 19162389 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt speech task with tongue movement, lip movement, and vowel phonation
Number of subjects: 0
Study 19162389 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel‐based meta‐analysis of syllable‐singing (11 studies)
Number of subjects: 0
Study 19162389 — intervention group
Group type: COMPARATOR
Intervention: Previously‐published meta‐analysis of oral reading (11 studies)
Number of subjects: 0
Study 17227801 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual iv administration of 4 mg zoledronate
Number of subjects: 43
Study 17227801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15189592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load participants
Number of subjects: 0
Study 15189592 — intervention group
Group type: EXPERIMENTAL
Intervention: No load participants (initial ratings)
Number of subjects: 0
Study 15189592 — intervention group
Group type: COMPARATOR
Intervention: No load participants (later ratings)
Number of subjects: 0
Study 10989241 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal ethinyl estradiol (EE) in Group A (n=14)
Number of subjects: 41
Study 10989241 — intervention group
Group type: COMPARATOR
Intervention: No therapy in Group B (n=12)
Number of subjects: 41
Study 8846126 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose 6-mercaptopurine (HD‐6MP) 1300 mg/m(2).24h
Number of subjects: 9
Study 8846126 — intervention group
Group type: COMPARATOR
Intervention: High dose 6-mercaptopurine (HD‐6MP) 1300 mg/m(2).24h with allopurinol (200 mg/m(2).day)
Number of subjects: 9
Study 1480728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg once daily, titrated up to 200 mg if necessary)
Number of subjects: 100
Study 6489485 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position for 4 hours
Number of subjects: 10
Study 6489485 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position for 0.5 h, 2 h, and 4 h
Number of subjects: 10
Study 6489485 — intervention group
Group type: COMPARATOR
Intervention: Upright position (control)
Number of subjects: 10
Study 6489485 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to upright position after supine
Number of subjects: 10
Study 6489485 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10
Study 3959273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined operation
Number of subjects: 70
Study 3959273 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery surgery performed first (staged procedure)
Number of subjects: 70
Study 30283911 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg daily)
Number of subjects: 1021
Study 30283911 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1021